Relatlimab
- Generic Name
- Relatlimab
- Brand Names
- Opdualag
- Drug Type
- Biotech
- CAS Number
- 1673516-98-7
- Unique Ingredient Identifier
- AF75XOF6W3
- Background
Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3). It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013, and has garnered interest in the treatment of a variety of cancers, including leukemia and melanoma. As immune checkpoint inhibitors have limited efficacy when used alone, drugs like relatlimab have been trialed in combination with other checkpoint inhibitors - for example, PD-1 inhibitors like nivolumab or CTLA-4 inhibitors like ipilimumab - to enhance their efficacy.
Relatlimab received FDA approval in March 2022, alongside the PD-1 inhibitor nivolumab in the combination product Opdualag (Bristol-Myers Squibb), for the treatment of unresectable or metastatic melanoma. It was the first anti-LAG-3 antibody demonstrate benefit in a Phase 3 study, as well as the first to receive FDA approval.
- Indication
Relatlimab is indicated in combination with nivolumab, in the combination product Opdualag, for the treatment of adult and pediatric patients ≥12 years old with unresectable or metastatic melanoma.
- Associated Conditions
- Metastatic Melanoma, Unresectable Melanoma
A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies
- Conditions
- Lymphoma, Non-HodgkinLymphoma, Large B-Cell, DiffuseLymphoma, Follicular
- Interventions
- First Posted Date
- 2017-10-16
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 62
- Registration Number
- NCT03310619
- Locations
- 🇺🇸
Local Institution - 015, Omaha, Nebraska, United States
🇺🇸Local Institution - 016, Philadelphia, Pennsylvania, United States
🇺🇸Local Institution - 011, Duarte, California, United States
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
- Conditions
- Gastric CancerEsophageal CancerGastroEsophageal Cancer
- Interventions
- First Posted Date
- 2017-02-07
- Last Posted Date
- 2025-03-06
- Target Recruit Count
- 32
- Registration Number
- NCT03044613
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Alleghany Health Network, Pittsburgh, Pennsylvania, United States
🇺🇸Baylor University/ Charles A. Sammons Cancer Center, Dallas, Texas, United States
Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer
- Conditions
- Colon Carcinoma
- Interventions
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 268
- Registration Number
- NCT03026140
- Locations
- 🇳🇱
Marieke van de Belt, Amsterdam, Netherlands
🇳🇱Catharina Ziekenhuis, Eindhoven, Netherlands
🇳🇱Spaarne Ziekenhuis, Haarlem, Netherlands
Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 35
- Registration Number
- NCT02966548
- Locations
- 🇯🇵
Local Institution - 0001, Kashiwa-shi, Chiba, Japan
An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors
- Conditions
- Various Advanced Cancer
- Interventions
- First Posted Date
- 2015-07-02
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 578
- Registration Number
- NCT02488759
- Locations
- 🇺🇸
Local Institution - 0003, Atlanta, Georgia, United States
🇧🇪Local Institution - 0012, Brussels, Belgium
🇺🇸Local Institution - 0033, Tampa, Florida, United States
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Conditions
- Advanced LymphomaAdvanced Malignant Solid NeoplasmBladder CarcinomaBreast CarcinomaCervical CarcinomaColon CarcinomaColorectal CarcinomaEndometrial CarcinomaEsophageal CarcinomaExocrine Pancreas Carcinoma
- Interventions
- Procedure: Biopsy ProcedureProcedure: Biospecimen CollectionProcedure: Computed TomographyOther: Cytology Specimen Collection ProcedureProcedure: Radiologic ExaminationProcedure: Multigated Acquisition ScanProcedure: Echocardiography TestOther: Laboratory Biomarker AnalysisProcedure: Magnetic Resonance ImagingProcedure: Radionuclide Imaging
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6452
- Registration Number
- NCT02465060
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸Thomas Hospital, Fairhope, Alabama, United States
🇺🇸Mobile Infirmary Medical Center, Mobile, Alabama, United States
A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread
- Conditions
- Microsatellite Stable Colorectal CancerMismatch Repair Proficient Colorectal CancerMicrosatellite Unstable Colorectal CancerMismatch Repair Deficient Colorectal Cancer
- Interventions
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 385
- Registration Number
- NCT02060188
- Locations
- 🇺🇸
Local Institution - 0028, Gilbert, Arizona, United States
🇺🇸Local Institution - 0004, Los Angeles, California, United States
🇺🇸Local Institution - 0036, Boston, Massachusetts, United States
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
- Conditions
- Neoplasms by Site
- Interventions
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1499
- Registration Number
- NCT01968109
- Locations
- 🇺🇸
Local Institution - 0002, Portland, Oregon, United States
🇯🇵Local Institution - 0052, Chuo-ku, Tokyo, Japan
🇺🇸Local Institution - 0043, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.